Unknown

Dataset Information

A Randomized Controlled Trial of Intranasal Neuropeptide Y in Patients With Major Depressive Disorder.


ABSTRACT:

Background

Since about one-third of patients with major depressive disorder (MDD) do not respond adequately to available antidepressants, there is a need for treatments based on novel mechanisms of action. Neuropeptide Y (NPY), a normal brain constituent, is reduced in cerebrospinal fluid of patients with MDD and post-traumatic stress disorder and in corresponding rodent models. Moreover, NPY administered centrally or intranasally rescues pathophysiology in these models. Consequently, we conducted the first, to our knowledge, controlled trial of NPY as a treatment for MDD.

Methods

Thirty MDD patients on a stable dose of a conventional antidepressant insufflated 6.8 mg NPY (n = 12) or placebo (n = 18) in a double blind randomized fashion. Effects were assessed at baseline, +1

SUBMITTER: Mathe AA 

PROVIDER: S-EPMC7770516 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature